# EDGAR Filing Document

**Accession Number:** 0001729149
**File Stem:** 0001729149-23-000039
**Filing Date:** 2023-3
**Character Count:** 28473
**Document Hash:** 43933f958fb60390abe127872cd5eec5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001729149-23-000039.hdr.sgml**: 20230302

**ACCESSION NUMBER**: 0001729149-23-000039

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230302

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230302

**DATE AS OF CHANGE**: 20230302

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VIEMED HEALTHCARE, INC.
- **CENTRAL INDEX KEY:** 0001729149
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38973
- **FILM NUMBER:** 23699894

**BUSINESS ADDRESS:**
- **STREET 1:** 625 E. KALISTE SALOOM RD.
- **CITY:** LAFAYETTE
- **STATE:** LA
- **ZIP:** 70508
- **BUSINESS PHONE:** 337.504.3802

**MAIL ADDRESS:**
- **STREET 1:** 625 E. KALISTE SALOOM RD.
- **CITY:** LAFAYETTE
- **STATE:** LA
- **ZIP:** 70508

?xml version="1.0" ? vmd-20230302

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 2, 2023**

**Viemed Healthcare, Inc.** 

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **British Columbia, Canada** | **001-38973** | **N/A** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **625 E. Kaliste Saloom Rd.**<br>**Lafayette, Louisiana** | **70508** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(337) 504-3802**

**(Registrant's telephone number, including area code)** 

**(Former name or former address, if changed since last report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered <br> <u>Common shares, no par value</u> <u>VMD</u> <u>The Nasdaq Stock Market LLC</u>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02. &nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On March 2, 2023, Viemed Healthcare, Inc. (the "Company") issued a press release announcing its financial results for the three months and year ended December 31, 2022. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the foregoing information, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information and Exhibit 99.1 be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

 *(d)* *Exhibits*

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |

---

<u>[99.1](q42022earningsrelease.htm)</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>[Press Release dated March 2, 2023.](q42022earningsrelease.htm)</u>

104 &nbsp;&nbsp;&nbsp;&nbsp;Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: **March 2, 2023**

---

| | |
|:---|:---|
| VIEMED HEALTHCARE, INC. | VIEMED HEALTHCARE, INC. |
| By: | /s/ Trae Fitzgerald |
|  | Trae Fitzgerald |
|  | Chief Financial Officer |

---

## Exhibit 99.1

**VIEMED HEALTHCARE ANNOUNCES 2022 FINANCIAL RESULTS**

Lafayette, Louisiana (March 2, 2023) Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX: VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, today reported its financial results for the three months and year ended December 31, 2022.

**Operational highlights (all dollar amounts are USD):**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net revenues attributable to the Company's core business for the quarter ended December 31, 2022 were $37.5 million, a new Company record and an increase of 30% over the quarter ended December 31, 2021. Net revenues attributable to the Company's core business for the quarter ended December 31, 2022 were up approximately 5% over the quarter ended September 30, 2022. Total net revenues for the year ended December 31, 2022 were $138.8 million, including $2.3 million of COVID-19 related contact and vaccine tracing services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income for the quarter and year ended December 31, 2022 totaled $2.4 million and $6.2 million, respectively. Adjusted EBITDA for the quarter and year ended December 31, 2022 totaled approximately $9.3 million and $30.0 million, respectively. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures can be found in the tables accompanying this press release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company had a cash balance of $16.9 million at December 31, 2022 ($28.4 million at December 31, 2021), an overall working capital balance of $20.9 million at December 31, 2022 ($29.5 million at December 31, 2021), and repaid all long-term debt as of December 31, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• During the year ended December 31, 2022, the Company repurchased and cancelled 1,794,163 common shares under the share repurchase program at a cost of $9.6 million, representing an average buyback price of $5.33 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company expects to generate net revenues attributable to its core business of approximately $38.0 million to $39.0 million during the first quarter of 2023.

"Our favorable resolution of the OIG matter, debt free balance sheet, and access to $90 million of additional liquidity through new credit facilities have us in an incredibly strong position to capitalize on the positive trends in our industry," said Casey Hoyt, Viemed's CEO. "The healthcare market and regulatory environment are stabilizing and we are at an inflection point of opportunity for both organic and inorganic growth. I'm extraordinarily proud of the current state of our organization and very excited about upcoming opportunities to treat a rapidly expanding patient base."

**Bell Ringing Ceremony**

On Monday, March 6, 2023 at 9:15 a.m. ET, representatives from Viemed will be in attendance at the Nasdaq MarketSite in Times Square while Casey Hoyt, CEO, rings the Opening Bell. A live stream of the Nasdaq Bell Ringing Ceremony will be available at: https://www.nasdaq.com/marketsite/bell-ringing-ceremony

**Conference Call Details**

The Company will host a conference call to discuss fourth quarter and year end results on Friday, March 3, 2023 at 11:00 a.m. ET.

Interested parties may participate in the call by dialing:

877-407-6176 (US Toll-Free)

201-689-8451 (International)

Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=cVEbVBdL

Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.

------

**ABOUT VIEMED HEALTHCARE, INC.**

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. Visit our website at www.viemed.com.

For further information, please contact:

Glen Akselrod

Bristol Capital

905-326-1888

glen@bristolir.com

Todd Zehnder

Chief Operating Officer

Viemed Healthcare, Inc.

337-504-3802

investorinfo@viemed.com

***Forward-Looking Statements***

*Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue guidance for the first quarter, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on the Company's patient base, revenues, employees, and equipment and supplies; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the Company's novel business model; the state of the capital markets; the availability of funds and resources to pursue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company's status as an emerging growth company and a smaller reporting company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 10-K, and with the securities regulatory authorities in certain provinces of Canada available at* www.sedar.com*. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.*

------

**VIEMED HEALTHCARE, INC.**

**CONSOLIDATED BALANCE SHEETS**

***(Expressed in thousands of U.S. Dollars, except share amounts)***

---

| | | |
|:---|:---|:---|
| | **At<br>December 31, 2022** | **At<br>December 31, 2021** |
| **ASSETS** | | |
| **Current assets** | | |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $16914 | $28408 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance for doubtful accounts of $8,483 and $7,031 at December 31, 2022 and December 31, 2021, respectively | 15379 | 12823 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory, net of inventory reserve of $— and $1,418 at December 31, 2022 and December 31, 2021, respectively | 3574 | 2457 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax receivable | 26 | 1893 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 3849 | 1729 |
| **Total current assets** | $39742 | $47310 |
| **Long-term assets** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 68437 | 62846 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity investments | 2155 | 2157 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt investment | 2000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax asset | 3119 | 4787 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term assets | 1590 | 862 |
| **Total long-term assets** | 77301 | 70652 |
| **TOTAL ASSETS** | $117043 | $117962 |
| **LIABILITIES** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade payables | $2650 | $3239 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 4624 | 3753 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 11092 | 8875 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of lease liabilities | 495 | 464 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt |  | 1480 |
| **Total current liabilities** | $18861 | $17811 |
| **Long-term liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 889 | 757 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term lease liabilities | 199 | 268 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt |  | 4306 |
| **Total long-term liabilities** | $1088 | $5331 |
| **TOTAL LIABILITIES** | $19949 | $23142 |
| **Commitments and Contingencies** |  |  |
| **SHAREHOLDERS' EQUITY** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock - No par value: unlimited authorized; 38,049,739 and 39,640,388 issued and outstanding as of December 31, 2022 and December 31, 2021, respectively | 15123 | 14014 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 12125 | 7749 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss |  | (278) |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 69846 | 73335 |
| **TOTAL SHAREHOLDERS' EQUITY** | $97094 | $94820 |
| **TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY** | $117043 | $117962 |

---

------

**VIEMED HEALTHCARE, INC.**

**CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME**

***(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| **Revenue** | $37508 | $31962 | $138832 | $117062 |
| Cost of revenue | 14612 | 12300 | 54152 | 43652 |
| **Gross profit** | $22896 | $19662 | $84680 | $73410 |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 17172 | 14240 | 68161 | 54893 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 722 | 612 | 2696 | 2110 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 1317 | 1305 | 5202 | 5150 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 241 | 233 | 1012 | 851 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on disposal of property and equipment | 178 | 144 | 346 | 448 |
| &nbsp;&nbsp;&nbsp;&nbsp; Other expense (income) | (268) | (1537) | (989) | (1622) |
| **Income from operations** | $3534 | $4665 | $8252 | $11580 |
| **Non-operating income and expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income from equity method investments | 82 | 459 | 935 | 1241 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net of interest income | (32) | (69) | (197) | (318) |
| **Net income before taxes** | 3584 | 5055 | 8990 | 12503 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | 1146 | 968 | 2768 | 3377 |
| **Net income** | $2438 | $4087 | $6222 | $9126 |
| **Other comprehensive income** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in unrealized gain/loss on derivative instruments, net of tax | (56) | 52 | 278 | 173 |
| **Other comprehensive income** | $(56) | $52 | $278 | $173 |
| **Comprehensive income** | $2382 | $4139 | $6500 | $9299 |
| **Net income per share** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.06 | $0.10 | $0.16 | $0.23 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.06 | $0.10 | $0.16 | $0.22 |
| **Weighted average number of common shares outstanding:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 38015795 | 39636606 | 38655403 | 39491117 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 39513158 | 40529206 | 39807434 | 40680947 |

---

------

**VIEMED HEALTHCARE, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

***(Expressed in thousands of U.S. Dollars)***

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2022** | **2021** |
| **Cash flows from operating activities** |  |  |
| Net income | $6222 | $9126 |
| Adjustments for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 15630 | 11312 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for uncollectible accounts | 10011 | 6895 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in inventory reserve | (1418) | 65 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | 5202 | 5150 |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions of earnings received from equity method investments | 1079 | 416 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income from equity method investments | (935) | (1241) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on disposal of property and equipment | 346 | 448 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income tax expense | 1746 | 3884 |
| Net change in working capital |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase in accounts receivable | (12567) | (7345) |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease (increase) in inventory | 301 | (212) |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase in prepaid expenses and other assets | (2838) | (226) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Decrease) increase in trade payables | (318) | 133 |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase in deferred revenue | 871 | 344 |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in accrued liabilities | 2549 | (4022) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in income tax payable/receivable | 1867 | (2233) |
| **Net cash provided by operating activities** | $27748 | $22494 |
| **Cash flows from investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of property and equipment | (22898) | (19743) |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment in equity investments | (141) | (599) |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment in debt security | (2000) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of property and equipment | 1063 | 596 |
| **Net cash used in investing activities** | $(23976) | $(19746) |
| **Cash flows from financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from exercise of options | 283 | 112 |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments on notes payable | (4475) | (152) |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments on term note | (1321) | (1683) |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares redeemed to pay income tax | (143) | (1434) |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares repurchased under the share repurchase program | (9568) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of lease liabilities | (42) | (2164) |
| **Net cash used in financing activities** | $(15266) | $(5321) |
| **Net decrease in cash and cash equivalents** | (11494) | (2573) |
| **Cash and cash equivalents at beginning of year** | 28408 | 30981 |
| **Cash and cash equivalents at end of period** | $16914 | $28408 |
| **Supplemental disclosures of cash flow information** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the period for interest | $231 | $351 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash (received) paid during the period for income taxes, net of refunds | $(846) | $1768 |
| **Supplemental disclosures of non-cash transactions** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net non-cash changes to finance leases | $— | $48 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net non-cash changes to operating lease | $530 | $712 |

---

------

**Non-GAAP Financial Measures**

This press release refers to "Adjusted EBITDA" which is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies. Adjusted EBITDA is defined as net income (loss) before interest expense, income tax expense (benefit), depreciation, and stock-based compensation. Management believes Adjusted EBITDA provides helpful information with respect to the Company's operating performance as viewed by management, including a view of the Company's business that is not dependent on the impact of the Company's capitalization structure and items that are not part of the Company's day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company's operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company's employees, (iii) for planning purposes, including the preparation of the Company's internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company's operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company's operating performance in the same manner as management. The following table is a reconciliation of net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:

**VIEMED HEALTHCARE, INC.**

**Reconciliation of Net Income to Non-GAAP Adjusted EBITDA**

***(Expressed in thousands of U.S. Dollars)***

***(Unaudited)***

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **For the quarter ended** | **December 31, 2022** | **September 30, 2022** | **June 30, 2022** | **March 31, 2022** | **December 31, 2021** | **September 30, 2021** | **June 30, 2021** | **March 31, 2021** |
| **Net Income** | $2438 | $1055 | $967 | $1762 | $4087 | $1789 | $1566 | $1684 |
| Add back: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Depreciation | 4373 | 4120 | 3740 | 3397 | 3120 | 2867 | 2716 | 2609 |
| &nbsp;&nbsp;Interest expense | 32 | 42 | 59 | 64 | 69 | 75 | 83 | 91 |
| &nbsp;&nbsp;Stock-based compensation | 1317 | 1309 | 1271 | 1305 | 1305 | 1302 | 1236 | 1307 |
| &nbsp;&nbsp;Income tax expense (benefit) | 1146 | 456 | 421 | 745 | 968 | 1386 | 1246 | (223) |
| **Adjusted EBITDA** | $**9306** | $**6982** | $**6458** | $**7273** | $**9549** | $**7419** | $**6847** | $**5468** |

---

---

| | |
|:---|:---|
| | **Year Ended December 31, 2022** |
| **Net Income** | $6222 |
| Add back: |  |
| &nbsp;&nbsp;Depreciation | 15630 |
| &nbsp;&nbsp;Interest expense | 197 |
| &nbsp;&nbsp;Stock-based compensation | 5202 |
| &nbsp;&nbsp;Income tax expense (benefit) | 2768 |
| **Adjusted EBITDA** | $**30019** |

---

**Use of Non-GAAP Financial Measures** 

Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. It is not a measurement of the Company's financial performance under U.S. GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with U.S. GAAP and may not be comparable to other similarly titled measures of other businesses. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company's operating results as reported under U.S. GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company's industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

------

**VIEMED HEALTHCARE, INC.**

**Key Financial and Operational Information**

***(Expressed in thousands of U.S. Dollars, except vent patients)***

***(Unaudited)***

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **For the quarter ended** | **December 31,<br>2022** | **September 30, 2022** | **June 30, 2022** | **March 31, 2022** | **December 31, 2021** | **September 30, 2021** | **June 30, 2021** | **March 31, 2021** |
| **Financial Information:** | **Financial Information:** | | | | | | | |
| Revenue | $37508 | $35759 | $33310 | $32255 | $31962 | $29285 | $27399 | $28416 |
| Gross Profit | 22896 | 21651 | 20390 | 19743 | 19662 | 18381 | 17625 | 17742 |
| Gross Profit % | 61% | 61% | 61% | 61% | 62% | 63% | 64% | 62% |
| Net Income | 2438 | 1055 | 967 | 1762 | 4087 | 1789 | 1566 | 1684 |
| Cash and Cash Equivalents (As of) | 16914 | 21478 | 21922 | 29248 | 28408 | 26867 | 31151 | 31097 |
| Total Assets (As of) | 117043 | 119419 | 115904 | 119007 | 117962 | 115486 | 111014 | 113001 |
| Adjusted EBITDA<sup>(1)</sup> | 9306 | 6982 | 6458 | 7273 | 9549 | 7419 | 6847 | 5468 |
| **Operational Information:** | **Operational Information:** |  |  |  |  |  |  |  |
| Vent Patients<sup>(2)</sup> | 9306 | 9127 | 8837 | 8434 | 8405 | 8200 | 8103 | 7733 |

---

<sup>(1)</sup> Refer to "Non-GAAP Financial Measures" section above for definition of Adjusted EBITDA.

<sup>(2)</sup> Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.

<br>